SMARCA2 and cancer: A recent study by Farnaby developed an optimized chemical ACBI1 that cooperatively targets SMARCA2, SMARCA4, and PBRM1, exhibiting significant antiproliferative and cell death-inducing effects in SMARCA4-mutant cancer cells [187].